Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Emricasan
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Histogen
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Histogen will retain ownership and oversight over emricasan and responsibility for all regulatory filings and maintaining its existing caspase inhibitor patent portfolio. Amerimmune will lead development efforts of emricasan in a phase 1 study in mild-CO...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 27, 2020
Lead Product(s) : Emricasan
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Histogen
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?